David Y. Léger

2.1k citations

57 papers · 1.8k indexed · h-index 25

Biomaterials top 5%
Toxicology top 5%
Molecular Medicine top 5%
Immunology and Allergy top 5%
Pharmacology top 5%
Pulmonary and Respiratory Medicine
- Photodynamic Therapy Research Studies 14
Biomedical Engineering
- Nanoplatforms for cancer theranostics 12
Molecular Biology
- Phytochemical Studies and Bioactivities 10
- Natural product bioactivities and synthesis 5
- Cell death mechanisms and regulation 5
- Bioactive Natural Diterpenoids Research 4
Materials Chemistry
- Porphyrin and Phthalocyanine Chemistry 9
Computational Mechanics
- Field-Flow Fractionation Techniques 4

Co-authors: Bertrand Liagre Jean‐Louis Beneytout Vincent Sol Frédérique Brégier Vincent Chaleix Mohamed Hmamouchi Robert Granet Aline Pinon
Cited by: Biomaterials Toxicology Molecular Medicine
Partner nations: France Lebanon Switzerland

In The Last Decade

David Y. Léger

57 papers receiving 1.7k citations

Peers

Countries citing papers authored by David Y. Léger

Since Specialization

Citations

This map shows the geographic impact of David Y. Léger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Y. Léger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Y. Léger more than expected).

Fields of papers citing papers by David Y. Léger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Y. Léger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Y. Léger. The network helps show where David Y. Léger may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Y. Léger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Y. Léger Line = papers co-authored together David Y. Léger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Effect of Photosensitizer Metalation Incorporated into Arene–Ruthenium Assemblies on Prostate Cancer Lucie Paulus,Manuel Gallardo‐Villagrán,Claire Carrion,Catherine Ouk,F. Martin,Bruno Therrien,David Y. Léger,Bertrand Liagre	2023	5
2	Design and synthesis of zinc protoporphyrin IX-adamantane/cyclodextrin/cellulose nanocrystals complexes for anticancer photodynamic therapy Gautier M.A. Ndong Ntoutoume,Robert Granet,Jean‐Pierre Mbakidi,Eléna Constantin,Ludovic Bretin,David Y. Léger,Bertrand Liagre,Vincent Chaleix,Frédérique Brégier,Vincent Sol	2021	15
3	In vitro anticancer activity of new gold(III) porphyrin complexes in colon cancer cells Fatima Dandash,David Y. Léger,Chloë Fidanzi-Dugas,Soumaya Nasri,Frédérique Brégier,Robert Granet,Walid Karam,Mona Diab‐Assaf,Vincent Sol,Bertrand Liagre	2017	27
4	Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: Observational single-center study of 122 patients David Y. Léger,Stéphane Moreau,N. Signol,J.B. Fargeas,Marie-Agnès Picat,Amélie Penot,Julie Abraham,Marie‐Laure Laroche,Dominique Bordessoule	2017	30
5	Delivery of tanshinone IIA and α-mangostin from gold/PEI/cyclodextrin nanoparticle platform designed for prostate cancer chemotherapy Shihong Qiu,Robert Granet,Jean‐Pierre Mbakidi,Frédérique Brégier,Christelle Pouget,Ludovic Micallef,Tan‐Sothéa Ouk,David Y. Léger,Bertrand Liagre,Vincent Chaleix,Vincent Sol	2016	40
6	Development of curcumin–cyclodextrin/cellulose nanocrystals complexes: New anticancer drug delivery systems Gautier M.A. Ndong Ntoutoume,Robert Granet,Jean Pierre Mbakidi,Frédérique Brégier,David Y. Léger,Chloë Fidanzi-Dugas,Vincent Lequart,Nicolas Joly,Bertrand Liagre,Vincent Chaleix,Vincent Sol	2015	160
7	Berberis libanotica extract targets NF-κB/COX-2, PI3K/Akt and mitochondrial/caspase signalling to induce human erythroleukemia cell apoptosis Saada Diab,Chloë Fidanzi,David Y. Léger,Lamia Ghezali,Marion Millot,F. Martin,Rania Azar,Fadi Esseily,Antoine M. Saab,Vincent Sol,Mona Diab‐Assaf,Bertrand Liagre	2015	17
8	Cyclopamine and jervine induce COX-2 overexpression in human erythroleukemia cells but only cyclopamine has a pro-apoptotic effect Lamia Ghezali,David Y. Léger,Youness Limami,Jeanne Cook‐Moreau,Jean‐Louis Beneytout,Bertrand Liagre	2013	24
9	Novel methylsulfonyl chalcones as potential antiproliferative drugs for human prostate cancer: Involvement of the intrinsic pathway of apoptosis Bassel Ismail,Lamia Ghezali,Rokhaya Gueye,Youness Limami,Christelle Pouget,David Y. Léger,F. Martin,Jean‐Louis Beneytout,Jean‐Luc Duroux,Mona Diab‐Assaf,Catherine Fagnère,Bertrand Liagre	2013	15
10	Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma Hana Janoušková,Anne Maglott,David Y. Léger,Catherine Bossert,Fanny Noulet,Éric Guérin,Dominique Guénot,Sophie Pinel,Pascal Chastagner,François Plénat,N. Entz-Werle,Jacqueline Lehmann‐Che,Julien Godet,Sophie Martin,Jan Teisinger,Monique Dontenwill	2012	104
11	The P2Y2/Src/p38/COX-2 pathway is involved in the resistance to ursolic acid-induced apoptosis in colorectal and prostate cancer cells Youness Limami,Aline Pinon,David Y. Léger,Émilie Pinault,Christiane Delage,Jean‐Louis Beneytout,Alain Simon,Bertrand Liagre	2012	61
12	HT-29 colorectal cancer cells undergoing apoptosis overexpress COX-2 to delay ursolic acid-induced cell death Youness Limami,Aline Pinon,David Y. Léger,Yoanne Mousseau,Jeanne Cook‐Moreau,Jean‐Louis Beneytout,Christiane Delage,Bertrand Liagre,Alain Simon	2011	44
13	Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells C. Lepage,David Y. Léger,Julian Bertrand,F. Martin,Jean‐Louis Beneytout,Bertrand Liagre	2010	112
14	Antiproliferative effect of extracts fromAristolochia baeticaandOriganum compactumon human breast cancer cell line MCF-7 Wahid Chaouki,David Y. Léger,Jamila Eljastimi,Jean‐Louis Beneytout,Mohamed Hmamouchi	2010	50
15	Citral inhibits cell proliferation and induces apoptosis and cell cycle arrest in MCF‐7 cells Wahid Chaouki,David Y. Léger,Bertrand Liagre,Jean‐Louis Beneytout,Mohamed Hmamouchi	2009	95
16	Sedimentation field flow fractionation to study human erythroleukemia cell megakaryocytic differentiation after short period diosgenin induction David Y. Léger,Serge Battu,Bertrand Liagre,Philippe Cardot,Jean‐Louis Beneytout	2007	18
17	Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents David Y. Léger,Bertrand Liagre,Jean‐Louis Beneytout	2006	25
18	Pre-apoptotic sub-population cell sorting from diosgenin apoptosis induced 1547 cells by Sedimentation Field-Flow Fractionation Gaëlle Bégaud,Serge Battu,Bertrand Liagre,David Y. Léger,Jean‐Louis Beneytout,Philippe Cardot	2006	20
19	Megakaryocyte cell sorting from diosgenin-differentiated human erythroleukemia cells by sedimentation field-flow fractionation David Y. Léger,Serge Battu,Bertrand Liagre,Jean‐Louis Beneytout,Philippe Cardot	2006	25
20	Diosgenin dose-dependent apoptosis and differentiation induction in human erythroleukemia cell line and sedimentation field-flow fractionation monitoring David Y. Léger,Bertrand Liagre,Philippe Jean Paul Cardot,Jean‐Louis Beneytout,Serge Battu	2004	47

About David Y. Léger

David Y. Léger is a scholar working on Toxicology, Pharmacology and Applied Microbiology and Biotechnology, having authored 57 papers that have together received 1.8k indexed citations. Recurring topics across this work include Photodynamic Therapy Research Studies (14 papers), Nanoplatforms for cancer theranostics (12 papers), Phytochemical Studies and Bioactivities (10 papers), Porphyrin and Phthalocyanine Chemistry (9 papers), Natural product bioactivities and synthesis (5 papers), Cell death mechanisms and regulation (5 papers), Bioactive Natural Diterpenoids Research (4 papers) and Field-Flow Fractionation Techniques (4 papers). The work is most often cited by research in Biomaterials (249 citations), Toxicology (65 citations) and Molecular Medicine (78 citations). David Y. Léger has collaborated with scholars based in France, Lebanon and Switzerland. Frequent co-authors include Bertrand Liagre, Jean‐Louis Beneytout, Vincent Sol, Frédérique Brégier, Vincent Chaleix, Mohamed Hmamouchi, Robert Granet, Aline Pinon, Bruno Therrien and Youness Limami.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact